Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation

Shalini Shenoy, Emanuele Angelucci, Staci D. Arnold, K. Scott Baker, Monica Bhatia, Dorine Bresters, Andrew C. Dietz, Josu De La Fuente, Christine Duncan, Javid Gaziev, Allison A. King, Michael A. Pulsipher, Angela R. Smith, Mark C. Walters

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Sustained donor engraftment after allogeneic hematopoietic cell transplantation (HCT) converts to healthy donor hemoglobin synthesis and halts disease symptoms in patients with sickle cell disease and thalassemia major. A disease-free survival probability that exceeds 90% has been reported when HCT using an HLA-matched sibling donor is performed in young patients with low-risk disease or treatment-related risk factors. Alternate donor HCT and HCT in adults is performed infrequently because of a higher risk profile. Transplant-specific risks include conditioning regimen-related toxicity, graft-versus-host disease, graft rejection with marrow aplasia or disease recurrence, and infections associated with immunosuppression and delayed immune reconstitution. The magnitude of risk depends on patient age, clinical status of the underlying disease (eg, organ injury from vasculopathy and iron overload), donor source, and intensity of the conditioning regimen. These risks are commonly monitored and reported in the short term. Documenting very late outcomes is important, but these data are rarely reported because of challenges imposed by patient drop-out and insufficient resources. This report summarizes long-term follow-up results after HCT for hemoglobin disorders, identifies gaps in knowledge, and discusses opportunities for future investigations. This consensus summary will be followed by a second article detailing comprehensive long-term follow-up recommendations to aid in maintaining health in these individuals and identifying late complication risks that could facilitate interventions to improve outcomes.

Original languageEnglish (US)
Pages (from-to)552-561
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number4
DOIs
StatePublished - Apr 1 2017

Keywords

  • Late effects
  • Pediatric stem cell transplant
  • Sickle cell disease
  • Thalassemia

Fingerprint Dive into the research topics of 'Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation'. Together they form a unique fingerprint.

  • Cite this